FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200582380> ?p ?o ?g. }

• W4200582380 endingPage "S711" @default.
• W4200582380 startingPage "S711" @default.
• W4200582380 abstract "Abstract Background Ceftazidime-avibactam (CAZ-AVI) is a β-lactam/non-β-lactam β-lactamase inhibitor combination that can inhibit class A, C, and some class D β-lactamases. Resistance caused by these β-lactamases often results in multidrug-resistance (MDR). This study evaluated the in vitro activity of CAZ-AVI and comparators against MDR Enterobacterales and Pseudomonas aeruginosa isolates collected from patients in Latin America. Methods Non-duplicate clinical isolates were collected in 2018-2019 in 10 countries in Latin America. Susceptibility testing was performed using CLSI broth microdilution and interpreted using CLSI 2021 and FDA (tigecycline) breakpoints. MDR was defined as resistant (R) to ≥3 of 7 sentinel drugs: amikacin (AMK), aztreonam (ATM), cefepime (FEP), colistin (CST), levofloxacin (LVX), meropenem (MEM), and piperacillin-tazobactam (TZP). Results The activity of CAZ-AVI and comparators against all isolates and MDR subsets is shown in the table. MDR rates for the studied species ranged from 16.3% among E. cloacae to 35.7% among K. pneumoniae. CAZ-AVI was active against 98% of Enterobacterales isolates and maintained activity against 74-98% of MDR isolates of the examined Enterobacterales species. Only tigecycline showed higher activity. Among P. aeruginosa, CAZ-AVI was active against 87% of all isolates and 47% of MDR isolates; no other studied drug was more active. The three most common MDR phenotypes among Enterobacterales were 1) R to ATM, FEP, and LVX (n=544, 44.8% of all MDR Enterobacterales; 100% susceptible (S) to CAZ-AVI), 2) R to ATM, FEP, LVX, and TZP (n=150, 12.4% of all MDR Enterobacterales; 99.3% S to CAZ-AVI), and 3) R to all sentinel drugs except AMK and CST (n=145, 11.9% of all MDR isolates; 78.6% S to CAZ-AVI). The three most common MDR phenotypes among P. aeruginosa were 1) R to all sentinel drugs except CST (n=85, 19.7% of all MDR isolates; 24.7% S to CAZ-AVI), 2) R to all sentinel drugs except AMK and CST (n=42, 9.7% of all MDR isolates; 66.7% S to CAZ-AVI), and 3) R to AMK, LVX, and MEM (n=37, 8.6% of all MDR isolates; 24.3% S to CAZ-AVI). Conclusion These in vitro data suggest that CAZ-AVI can be an effective treatment option for infections caused by MDR Enterobacterales and P. aeruginosa collected in Latin America. Disclosures Sibylle Lob, PhD, IHMA (Employee)Pfizer, Inc. (Independent Contractor) Meredith Hackel, PhD MPH, IHMA (Employee)Pfizer, Inc. (Independent Contractor) Gregory Stone, PhD, AztraZeneca (Shareholder, Former Employee)Pfizer, Inc. (Employee) Daniel F. Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Independent Contractor)" @default.
• W4200582380 created "2021-12-31" @default.
• W4200582380 creator A5017159626 @default.
• W4200582380 creator A5020290756 @default.
• W4200582380 creator A5020992600 @default.
• W4200582380 creator A5038009031 @default.
• W4200582380 date "2021-11-01" @default.
• W4200582380 modified "2023-10-16" @default.
• W4200582380 title "1244. In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against MDR Enterobacterales and Pseudomonas aeruginosa Collected in Latin America During the ATLAS Global Surveillance Program 2018-2019" @default.
• W4200582380 doi "https://doi.org/10.1093/ofid/ofab466.1436" @default.
• W4200582380 hasPublicationYear "2021" @default.
• W4200582380 type Work @default.
• W4200582380 citedByCount "0" @default.
• W4200582380 crossrefType "journal-article" @default.
• W4200582380 hasAuthorship W4200582380A5017159626 @default.
• W4200582380 hasAuthorship W4200582380A5020290756 @default.
• W4200582380 hasAuthorship W4200582380A5020992600 @default.
• W4200582380 hasAuthorship W4200582380A5038009031 @default.
• W4200582380 hasBestOaLocation W42005823801 @default.
• W4200582380 hasConcept C104317684 @default.
• W4200582380 hasConcept C176947019 @default.
• W4200582380 hasConcept C2775933652 @default.
• W4200582380 hasConcept C2776968632 @default.
• W4200582380 hasConcept C2777027569 @default.
• W4200582380 hasConcept C2777050379 @default.
• W4200582380 hasConcept C2777058267 @default.
• W4200582380 hasConcept C2777402170 @default.
• W4200582380 hasConcept C2777637488 @default.
• W4200582380 hasConcept C2778193466 @default.
• W4200582380 hasConcept C2779259085 @default.
• W4200582380 hasConcept C2779631663 @default.
• W4200582380 hasConcept C2780950330 @default.
• W4200582380 hasConcept C4937899 @default.
• W4200582380 hasConcept C501593827 @default.
• W4200582380 hasConcept C523546767 @default.
• W4200582380 hasConcept C54355233 @default.
• W4200582380 hasConcept C547475151 @default.
• W4200582380 hasConcept C55493867 @default.
• W4200582380 hasConcept C71924100 @default.
• W4200582380 hasConcept C86803240 @default.
• W4200582380 hasConcept C89423630 @default.
• W4200582380 hasConcept C94665300 @default.
• W4200582380 hasConceptScore W4200582380C104317684 @default.
• W4200582380 hasConceptScore W4200582380C176947019 @default.
• W4200582380 hasConceptScore W4200582380C2775933652 @default.
• W4200582380 hasConceptScore W4200582380C2776968632 @default.
• W4200582380 hasConceptScore W4200582380C2777027569 @default.
• W4200582380 hasConceptScore W4200582380C2777050379 @default.
• W4200582380 hasConceptScore W4200582380C2777058267 @default.
• W4200582380 hasConceptScore W4200582380C2777402170 @default.
• W4200582380 hasConceptScore W4200582380C2777637488 @default.
• W4200582380 hasConceptScore W4200582380C2778193466 @default.
• W4200582380 hasConceptScore W4200582380C2779259085 @default.
• W4200582380 hasConceptScore W4200582380C2779631663 @default.
• W4200582380 hasConceptScore W4200582380C2780950330 @default.
• W4200582380 hasConceptScore W4200582380C4937899 @default.
• W4200582380 hasConceptScore W4200582380C501593827 @default.
• W4200582380 hasConceptScore W4200582380C523546767 @default.
• W4200582380 hasConceptScore W4200582380C54355233 @default.
• W4200582380 hasConceptScore W4200582380C547475151 @default.
• W4200582380 hasConceptScore W4200582380C55493867 @default.
• W4200582380 hasConceptScore W4200582380C71924100 @default.
• W4200582380 hasConceptScore W4200582380C86803240 @default.
• W4200582380 hasConceptScore W4200582380C89423630 @default.
• W4200582380 hasConceptScore W4200582380C94665300 @default.
• W4200582380 hasIssue "Supplement_1" @default.
• W4200582380 hasLocation W42005823801 @default.
• W4200582380 hasLocation W42005823802 @default.
• W4200582380 hasOpenAccess W4200582380 @default.
• W4200582380 hasPrimaryLocation W42005823801 @default.
• W4200582380 hasRelatedWork W2072511609 @default.
• W4200582380 hasRelatedWork W2392734635 @default.
• W4200582380 hasRelatedWork W2557234235 @default.
• W4200582380 hasRelatedWork W2936290142 @default.
• W4200582380 hasRelatedWork W2944808759 @default.
• W4200582380 hasRelatedWork W2958591958 @default.
• W4200582380 hasRelatedWork W3215674769 @default.
• W4200582380 hasRelatedWork W4200582380 @default.
• W4200582380 hasRelatedWork W4232272478 @default.
• W4200582380 hasRelatedWork W4306644058 @default.
• W4200582380 hasVolume "8" @default.
• W4200582380 isParatext "false" @default.
• W4200582380 isRetracted "false" @default.
• W4200582380 workType "article" @default.